Evaluation of cellular proliferation markers in patients with myelodysplastic syndromes.

被引:0
|
作者
Ismail, SO
Mutema, G
Perrotta, G
Hornback, B
Wibowo, A
Mazzella, F
KowalVern, A
Schumacher, HR
机构
[1] UNIV CINCINNATI,MED CTR,DEPT PATHOL & LAB MED,CINCINNATI,OH 45267
[2] LOYOLA UNIV,MED CTR,MAYWOOD,IL 60153
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:4040 / 4040
页数:1
相关论文
共 50 条
  • [31] Evaluation of immature platelet fraction in patients with myelodysplastic syndromes. Association with poor prognosis factors
    Larruzea Ibarra, Alex
    Munoz Marin, Luz
    Perea Duran, Granada
    Torra Puig, Montserrat
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2019, 57 (06) : E128 - E130
  • [32] In vitro proliferation and differentiation of megakaryocytic progenitors in patients with aplastic anaemia, paroxysmal nocturnal haemoglobinuria and the myelodysplastic syndromes.
    Cox, CV
    Killick, S
    Elebute, MO
    Marsh, JCW
    Gordan-Smith, EC
    Gibson, FM
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 122 - 122
  • [33] Characterization of defective in vitro megakaryocytic development in patients with myelodysplastic syndromes.
    Hofmann, WK
    Kalina, U
    Wagner, S
    Ries, C
    Hoelzer, D
    Ottmann, OG
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 454 - 454
  • [34] Prognostic relevance of cytogenetic subgroups in 357 patients with myelodysplastic syndromes.
    Haase, D
    Schanz, J
    Wulich, J
    Schoch, C
    Freund, M
    Haferlach, T
    Wormann, B
    Staib, P
    Lentini, G
    Bartels, H
    Geissler, RG
    Germing, U
    Dorges, U
    Fonatsch, C
    Hiddemann, W
    BLOOD, 1997, 90 (10) : 2232 - 2232
  • [35] Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes.
    Urrutia, Samuel
    Sasaki, Koji
    Kantarjian, Hagop M.
    Jabbour, Elias
    Chien, Kelly Sharon
    Hammond, Danielle
    Bueso-Ramos, Carlos E.
    Khoury, Joseph
    Patel, Keyur P.
    Montalban-Bravo, Guillermo
    Wei, Yue
    Colla, Simona
    Short, Nicholas James
    Daver, Naval Guastad
    Borthakur, Gautam
    Kadia, Tapan M.
    Pierce, Sherry
    Wierda, William G.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Determination of LTC-IC numbers in patients with myelodysplastic syndromes.
    Sato, T
    Kim, S
    Selleri, C
    Young, NS
    Maciejewski, JP
    BLOOD, 1996, 88 (10) : 1338 - 1338
  • [37] Molecular abnormalities and clonality in myelodysplastic syndromes.
    Fenaux, P
    Preudhomme, C
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 556 - 560
  • [38] Myelodysplastic syndromes. Diagnosis and therapeutic strategies
    Aul, C
    Giagounidis, A
    Germing, U
    Ganser, A
    MEDIZINISCHE KLINIK, 2002, 97 (11) : 666 - 676
  • [39] Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
    Pollio, B.
    Ciriello, M. M.
    Fruttero, A.
    Geuna, M.
    Iavarone, A.
    Omede, P.
    Pautasso, M.
    Pollono, A. M.
    Santagostino, A.
    Garbaccio Ioria, G.
    Stacchini, A.
    Gioia, D.
    Ferrero, D.
    Marmont, F.
    Gallamini, A.
    Saglio, G.
    Levis, Alessandro
    Girotto, M.
    BLOOD, 2006, 108 (11) : 740A - 740A
  • [40] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes.
    Killick, S
    Marsh, JCW
    Cavenagh, J
    Mijovic, A
    Mufti, G
    Gordon-Smith, EC
    Bowen, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 69 - 69